SCHEMBL6479918

SCHEMBL6479918

C[SiH](C)OC(c1cccc(N2CCOCC2)n1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ POLB P06746 1/20 0.36
▸ PDE10A Q9Y233 4/20 0.36
▸ HTT P42858 1/20 0.35
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ ACACB O00763 1/20 0.34
▸ PRKDC P78527 1/20 0.34
▸ PIK3CB P42338 2/20 0.34
▸ ATR Q13535 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4547898 0.75 GAA (0.48) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL23006122 0.71 KMT2A (0.42) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5719027 0.71 IRAK4 (0.38) —
SCHEMBL6843345 0.71 GAA (0.59) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27435363 0.70 ADRB1 (0.40) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10183379 0.69 LMNA (0.50) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL22481105 0.69 ADRB1 (0.53) GAAALDH1A1SMN1; SMN2PDE10ACYP1A2
SCHEMBL22481109 0.69 ADRB1 (0.53) GAAALDH1A1SMN1; SMN2PDE10ACYP1A2
SCHEMBL10739039 0.69 POLB (0.46) GAAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1515189 0.67 HTR3E (0.66) GAAKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900209-B2 Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition MERCK SHARP & DOHME LTD. 2005-05-31 — — US disclosed
US-20040043982-A1 Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition MERCK SHARP & DOHME LTD. (GB) 2004-03-04 — — US disclosed
WO-2002042305-A1 NITROGEN SUBSTITUTED 1,2,4-TRIAZOLO[3,4-A]PHTHALAZINE DERIVATIVES FOR ENHANCING COGNITION MERCK SHARP & DOHME LIMITED (GB) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043982-A1 Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition PSEN1, BDNF, H1-5 GAA 2316/4885KDM4E 1288/4885ALDH1A1 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback